|
|
| Line 3: |
Line 3: |
| | | | |
| | <h2>Design</h2> | | <h2>Design</h2> |
| − | | + | VLPs are essentially “hollow-core” virus particles formed by self-assembly of HA, NA, and M1. It is generally accepted that VLPs that retain the structure and antigenicity of the infectious virions may have a better immunogenicity and be more immune protective than recombinant HA. By immunization,three structural proteins may have a synergistic effect on the immune response. VLPs could also induce a broader immune response than a corresponding whole-virion vaccine and have a more dominant Th1 response than a recombinant HA vaccine in mice and ferrets. Research also proved that both HA and NA can stimulate protective immune responses including both humoral and cellular immunity in animals and humans. VLPsalsohavethepotentialforactivatingboththeendogenousandexogenousantigen pathways leading to the presentation of viral peptides by MHC class I and class II molecules. Particles,unlike single proteins, have the ability to bind and enter cells using appropriate surface receptors. VLPs can be processed and presented on MHC class I molecules, therefore promoting presentation to T-cells |
| − | <p>
| + | by professional antigen presenting cells. So in conclusion, our design of VLP does have a promising chance of becoming a revolutionary cure for influenza and maybe other diseases. |
| − | By talking about your design work on this page, there is one medal criterion that you can attempt to meet, and one award that you can apply for. If your team is going for a gold medal by building a functional prototype, you should tell us what you did on this page. If you are going for the <a href="https://2015.igem.org/Judging/Awards#SpecialPrizes">Applied Design award</a>, you should also complete this page and tell us what you did.
| + | |
| − | </p>
| + | |
| − | | + | |
| − | <div class="highlightBox">
| + | |
| − | <h4>Note</h4>
| + | |
| − | <p>In order to be considered for the <a href="https://2015.igem.org/Judging/Awards#SpecialPrizes">Best Applied Design award</a> and/or the <a href="https://2015.igem.org/Judging/Awards#Medals">functional prototype gold medal criterion</a>, you must fill out this page.</p>
| + | |
| − | </div>
| + | |
| − | | + | |
| − | <p>This is a prize for the team that has developed a synthetic biology product to solve a real world problem in the most elegant way. The students will have considered how well the product addresses the problem versus other potential solutions, how the product integrates or disrupts other products and processes, and how its lifecycle can more broadly impact our lives and environments in positive and negative ways.</p>
| + | |
| − | | + | |
| − | <p>
| + | |
| − | If you are working on art and design as your main project, please join the art and design track. If you are integrating art and design into the core of your main project, please apply for the award by completing this page.
| + | |
| − | </p>
| + | |
| − | | + | |
| − | </div>
| + | |
| | | | |
| | </html> | | </html> |
Latest revision as of 02:47, 19 September 2015
Add a banner to your wiki!
You can make the image 980px by 200px
Remember to call the file: "Team_Nanjing_NFLS_banner.jpg"
Design
VLPs are essentially “hollow-core” virus particles formed by self-assembly of HA, NA, and M1. It is generally accepted that VLPs that retain the structure and antigenicity of the infectious virions may have a better immunogenicity and be more immune protective than recombinant HA. By immunization,three structural proteins may have a synergistic effect on the immune response. VLPs could also induce a broader immune response than a corresponding whole-virion vaccine and have a more dominant Th1 response than a recombinant HA vaccine in mice and ferrets. Research also proved that both HA and NA can stimulate protective immune responses including both humoral and cellular immunity in animals and humans. VLPsalsohavethepotentialforactivatingboththeendogenousandexogenousantigen pathways leading to the presentation of viral peptides by MHC class I and class II molecules. Particles,unlike single proteins, have the ability to bind and enter cells using appropriate surface receptors. VLPs can be processed and presented on MHC class I molecules, therefore promoting presentation to T-cells
by professional antigen presenting cells. So in conclusion, our design of VLP does have a promising chance of becoming a revolutionary cure for influenza and maybe other diseases.